GO:0038061 non-canonical NF-kappaB signal transduction: NIK-IKKalpha-p100 Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0038061 describes an intracellular signaling cassette in which NIK-dependent activation of IKKalpha leads to p100 processing and release of active p52 NF-kappaB dimers.
• The pathway is typically triggered by TNF receptor superfamily ligands including LTB, CD40, OX40, RANK, TWEAK and BAFF.
• Core signaling components include NIK (MAP3K14), IKKalpha (CHUK), NF-kappaB2 (p100/p52), RelB and TRAF proteins.
• Non-canonical NF-kappaB signaling controls lymphoid organogenesis, B-cell maturation, osteoclastogenesis and immune homeostasis.
• Dysregulated non-canonical signaling is implicated in autoimmunity, chronic inflammation and multiple cancers.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal dissection of this pathway in disease contexts.
Description
GO:0038061, non-canonical NF-kappaB signal transduction, is a biological process that defines an intracellular signaling cassette characterized by NIK-dependent processing and activation of NF-kappaB. Unlike the canonical NF-kappaB pathway, which relies on IKKbeta-mediated IkappaBalpha degradation, the non-canonical route depends on NF-kappaB-inducing kinase (NIK) phosphorylating and activating IkappaB kinase alpha (IKKalpha), which in turn phosphorylates the NF-kappaB2 protein p100, leading to its processing and release of active p52. This pathway is generally activated by ligands of the TNF receptor superfamily, including lymphotoxin beta (LTB), CD40, OX40, RANK, TWEAK and B cell-activating factor (BAFF). Researchers study GO:0038061 because it is a central regulator of immunity and inflammation, and because its dysregulation contributes to autoimmunity, chronic inflammatory disease and cancer. The pathway is also a therapeutic target: inhibition of LTbetaR signaling has been shown to activate WNT-induced regeneration in lung, and targeting NF-kappaB signaling is an active area of clinical investigation. In cancer, non-canonical NF-kappaB signaling can maintain tumor stem cells and shape the tumor microenvironment, as shown for IFI35 in glioblastoma stem cells and tumor-associated macrophage recruitment. Because the pathway is defined by a specific kinase cascade and a specific substrate-processing event, it is well suited to genetic dissection. CRISPR-based knockout, point-mutation, knock-in and overexpression models allow researchers to test which components are required for p100 processing, p52 generation and downstream transcriptional outputs in defined cell types. This article summarizes the QuickGO definition, the major stages of the pathway, the key genes involved, disease links and the experimental methods used to study GO:0038061.
non-canonical NF-kappaB signal transduction At A Glance
| GO ID | GO:0038061 |
|---|---|
| GO term | non-canonical NF-kappaB signal transduction |
| Ontology | biological_process |
| Synonym | NIK/NF-kappaB signaling; NIK-IKK-alpha cascade; p52-dependent NF-kappaB signaling; noncanonical NF-kappaB signaling |
| Major function | NIK-dependent processing and activation of NF-kappaB, producing active p52-containing dimers |
| Key kinase | NIK (MAP3K14) |
| Key IKK subunit | IKKalpha (CHUK) |
| Key substrate | NF-kappaB2 p100/p52 |
| Typical activators | LTB, CD40, OX40, RANK, TWEAK, BAFF |
What Is GO:0038061?
In our own words, GO:0038061 (non-canonical NF-kappaB signal transduction) is an intracellular signaling cassette that begins with activation of the NF-kappaB-inducing kinase (NIK). Activated NIK phosphorylates and activates IkappaB kinase alpha (IKKalpha). IKKalpha then phosphorylates the NF-kappaB2 protein p100, which leads to p100 processing and release of an active NF-kappaB subunit, p52. The pathway is generally activated by ligands of the TNF receptor superfamily, including lymphotoxin beta (LTB), CD40, OX40, RANK, TWEAK and B cell-activating factor (BAFF).
Why Is non-canonical NF-kappaB signal transduction Important in Cell Biology?
GO:0038061 is important because it provides a distinct, NIK-dependent route to NF-kappaB activation that is essential for lymphoid organ development, B-cell survival and maturation, osteoclastogenesis and immune homeostasis. Unlike the canonical pathway, which responds rapidly to many stimuli, the non-canonical pathway is slower and depends on stabilization of NIK and processing of p100, making it a uniquely regulated signaling module. Its dysregulation is linked to autoimmunity, chronic inflammation and cancer, and it is being explored as a therapeutic target. In addition, non-canonical NF-kappaB signaling can operate in tumor cells and in the tumor microenvironment, for example by maintaining glioblastoma stem cells and recruiting tumor-associated macrophages.
• Controls lymphoid organogenesis and secondary lymphoid tissue development.
• Regulates B-cell survival, maturation and antibody responses.
• Drives osteoclastogenesis and bone remodeling through RANK signaling.
• Contributes to autoimmunity and chronic inflammatory disease.
• Is implicated in multiple cancers, including hematologic and solid tumors.
• Can maintain cancer stem cells and modulate the tumor microenvironment.
• Is a target for therapeutic intervention, including LTbetaR inhibition in lung regeneration.
• Interacts with DNA-damage and innate immune signaling, including STING- and ATM/IFI16-dependent NF-kappaB activation.
• Provides a genetically tractable pathway for CRISPR-based causal studies.
• Has clinical relevance for NF-kappaB-targeted therapies.
What Happens During non-canonical NF-kappaB signal transduction?
Receptor triggering by TNF receptor superfamily ligands
In simple terms: The pathway starts when certain immune signals bind to receptors on the cell surface.
The non-canonical NF-kappaB pathway is generally activated by ligands of the TNF receptor superfamily, including lymphotoxin beta (LTB), CD40, OX40, RANK, TWEAK and B cell-activating factor (BAFF). Ligand binding to these receptors initiates the signaling cassette defined by GO:0038061.
NIK stabilization and activation
In simple terms: A kinase called NIK must accumulate and become active for the pathway to proceed.
The pathway begins with activation of the NF-kappaB-inducing kinase (NIK). NIK is the central kinase of the non-canonical cascade, and its activation is a defining step of GO:0038061.
IKKalpha phosphorylation and activation
In simple terms: NIK turns on another kinase, IKKalpha, by adding phosphate groups.
Activated NIK phosphorylates and activates IkappaB kinase alpha (IKKalpha). IKKalpha is the key IKK subunit in this pathway, distinguishing it from the canonical pathway that relies on IKKbeta.
p100 phosphorylation and processing to p52
In simple terms: IKKalpha marks the p100 protein so that it is trimmed into its active p52 form.
IKKalpha phosphorylates the NF-kappaB2 protein p100, leading to p100 processing and release of an active NF-kappaB subunit, p52. This processing event is the hallmark of non-canonical NF-kappaB activation.
Nuclear p52-RelB transcriptional activity
In simple terms: The active p52 protein moves into the nucleus to switch on target genes.
The released p52 participates in active NF-kappaB dimers that regulate transcription. Through this output, GO:0038061 controls gene expression programs important for immunity and inflammation.
Crosstalk with DNA damage and innate immune signaling
In simple terms: Other stress signals can also feed into this pathway.
Non-canonical NF-kappaB signaling can be activated downstream of DNA damage and innate immune sensing, including non-canonical activation of the DNA sensing adaptor STING by ATM and IFI16 after nuclear DNA damage. This crosstalk expands the biological contexts in which GO:0038061 operates.
Key Genes Involved in GO:0038061 non-canonical NF-kappaB signal transduction
The following genes and proteins are core components or regulators of GO:0038061, non-canonical NF-kappaB signal transduction.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MAP3K14 (NIK) | Central kinase that initiates the non-canonical cascade | Primary target for pathway inhibition and knockout studies |
| CHUK (IKKalpha) | Phosphorylates p100 to trigger processing | Key effector kinase distinguishing non-canonical from canonical signaling |
| NFKB2 (p100/p52) | Substrate whose processing releases active p52 | Readout of pathway activation and target for mutation studies |
| RELB | Dimerization partner of p52 | Marker of non-canonical NF-kappaB transcriptional activity |
| LTBR | Receptor for lymphotoxin beta | Target for lung regeneration studies via LTbetaR inhibition |
| CD40 | TNF receptor superfamily activator | Important in B-cell and immune signaling research |
| TNFRSF4 (OX40) | TNF receptor superfamily activator | Relevant to T-cell costimulation studies |
| TNFRSF11A (RANK) | TNF receptor superfamily activator | Central to osteoclastogenesis research |
| TNFRSF12A (TWEAK receptor) | TNF receptor superfamily activator | Studied in tissue remodeling and inflammation |
| TNFSF13B (BAFF) | Ligand that activates non-canonical signaling | Relevant to B-cell survival and autoimmunity |
| TRAF2 | Adapter linking receptors to NIK regulation | Commonly studied in pathway activation assays |
| TRAF3 | Negative regulator of NIK stability | Knockout increases non-canonical signaling |
| TBK1 | Kinase implicated in NF-kappaB-related signaling | Relevant to KRAS-driven cancer dependencies |
| IFI35 | Regulates non-canonical NF-kappaB signaling | Studied in glioblastoma stem cell maintenance |
| STING1 | DNA sensing adaptor linked to non-canonical NF-kappaB activation | Studied in DNA damage responses |
| ATM | DNA damage kinase that can activate STING-dependent NF-kappaB signaling | Relevant to nuclear DNA damage research |
| IFI16 | DNA sensor cooperating with ATM and STING | Studied in innate immune signaling |
| B cells (marker context) | B cells can disrupt tertiary lymphoid structures and suppress anti-tumor immunity | Relevant to tumor immunology studies |
How Is non-canonical NF-kappaB signal transduction Regulated?
GO:0038061 is regulated at multiple levels. NIK abundance and activity are controlled by upstream adapters such as TRAF proteins, and the pathway depends on NIK-dependent activation of IKKalpha and subsequent p100 processing. The pathway is generally activated by TNF receptor superfamily ligands including LTB, CD40, OX40, RANK, TWEAK and BAFF, which provide stimulus-specific control. In addition, non-canonical NF-kappaB signaling can be activated by DNA damage and innate immune sensing through ATM, IFI16 and STING, linking it to genome surveillance and inflammation. Because NF-kappaB signaling is broadly relevant to disease, pharmacological and genetic regulation of this pathway is an active therapeutic area.
non-canonical NF-kappaB signal transduction and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IFI35 | Glioblastoma stem cell maintenance and macrophage recruitment | Knockout and overexpression in glioblastoma cell models |
| LTBR | Lung regeneration via WNT signaling | Ligand/receptor inhibition in lung organoid or animal models |
| TBK1 | KRAS-driven cancer dependency | RNAi or CRISPR knockout in KRAS-mutant cancer lines |
| STING1/ATM/IFI16 | DNA damage-induced NF-kappaB signaling | Knockout and point-mutation models in DNA damage assays |
| B-cell-related genes | Tertiary lymphoid structure formation and anti-tumor immunity | B-cell depletion or knockout in tumor models |
Cancer and tumor microenvironment
Dysregulated NF-kappaB signaling, including the non-canonical pathway, is implicated in cancer, and targeting NF-kappaB signaling is being explored therapeutically. In glioblastoma, IFI35 regulates non-canonical NF-kappaB signaling to maintain glioblastoma stem cells and recruit tumor-associated macrophages, linking GO:0038061 to tumor stemness and immune microenvironment remodeling. In KRAS-driven cancers, RNA interference screens revealed dependencies involving TBK1, a kinase connected to NF-kappaB-related signaling. B cells can also disrupt tertiary lymphoid structure formation and suppress anti-tumor immunity, highlighting the immunological context in which non-canonical NF-kappaB signaling operates.
Autoimmunity and chronic inflammation
The non-canonical NF-kappaB pathway is a central regulator of immunity and inflammation, and its dysregulation contributes to autoimmune and inflammatory disease. Because the pathway is activated by BAFF, CD40 and other TNF receptor superfamily ligands, it is mechanistically linked to B-cell survival and immune activation programs relevant to autoimmunity.
Lung regeneration and tissue remodeling
Inhibition of LTbetaR signaling activates WNT-induced regeneration in lung, demonstrating that modulating a receptor upstream of non-canonical NF-kappaB signaling can influence tissue repair. This connects GO:0038061 to regenerative biology and suggests that pathway modulation may have therapeutic potential beyond inflammation.
DNA damage and innate immune signaling
Non-canonical activation of the DNA sensing adaptor STING by ATM and IFI16 mediates NF-kappaB signaling after nuclear DNA damage, directly linking GO:0038061 to genome surveillance and innate immunity. This has implications for understanding how DNA damage and inflammation intersect in disease.
From non-canonical NF-kappaB signal transduction-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is NIK required for p100 processing? | MAP3K14 knockout cell line |
| Does IKKalpha kinase activity drive p52 generation? | CHUK point-mutation (kinase-dead) knock-in |
| How does p100 processing affect transcription? | NFKB2 knock-in or processing-site mutation |
| Does a candidate gene regulate non-canonical NF-kappaB signaling? | CRISPR knockout followed by p52 readout |
| Can pathway activation be tracked in live cells? | Tagged knock-in of RELB or NFKB2 |
| Does overexpression of a regulator activate the pathway? | Overexpression cell model with p100/p52 immunoblot |
How to Study the non-canonical NF-kappaB signal transduction Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Western blot | p100 and p52 protein levels | Pathway activation readout |
| RNA-seq | Transcriptional output of p52 dimers | Gene expression profiling in knockout models |
| Proteomics | Protein abundance and interactions | Mapping pathway complexes |
| Imaging | NF-kappaB nuclear translocation | Live-cell pathway dynamics |
| Reporter assay | NF-kappaB transcriptional activity | Screening pathway modulators |
| CRISPR knockout | Gene requirement for pathway activation | Causal gene discovery |
| CRISPR knock-in | Tagged or mutant pathway components | Tracking and mechanistic studies |
| Overexpression | Sufficiency of a regulator to activate the pathway | Gain-of-function studies |
Western blotting of p100 and p52
Because p100 processing to p52 is the hallmark of GO:0038061, immunoblotting for p100 and p52 is a standard readout of pathway activation. This method directly measures the processing event that defines the non-canonical cascade.
RNA-seq and transcriptional profiling
RNA-seq can measure transcriptional outputs downstream of p52-containing NF-kappaB dimers, providing a global view of pathway activity. It is useful for comparing knockout, point-mutation and overexpression models to identify pathway-dependent gene programs.
Proteomics and interactomics
Proteomic approaches can identify NIK, IKKalpha and p100-associated complexes and quantify pathway component abundance. Such methods help define the molecular composition of the signaling cassette and its regulation.
Imaging and reporter assays
Fluorescence imaging and reporter assays can track NF-kappaB nuclear translocation and transcriptional activity in live cells. These approaches are valuable for studying pathway dynamics in immune and cancer cells.
How CRISPR Can Be Used to Study GO:0038061 non-canonical NF-kappaB signal transduction
Knockout
CRISPR knockout of MAP3K14 (NIK), CHUK (IKKalpha) or NFKB2 can abolish p100 processing and p52 generation, providing causal evidence that a gene is required for GO:0038061. Knockout models are also used to test candidate regulators such as IFI35 in disease-relevant cells.
Point Mutation
Point-mutation models, such as kinase-dead CHUK or processing-site mutants of NFKB2, allow researchers to separate kinase activity from scaffolding functions within the non-canonical cascade. These models are valuable for defining the precise molecular steps of GO:0038061.
Knock-in
Knock-in of tags or reporters into RELB or NFKB2 enables tracking of pathway activation and dimer localization in live cells. Knock-in approaches can also introduce disease-associated variants to study their impact on non-canonical NF-kappaB signaling.
Overexpression
Overexpression of NIK, IKKalpha or candidate regulators can test sufficiency for pathway activation and p52 production. Overexpression models are useful for gain-of-function studies in cancer and immune cells.
How EDITGENE Supports non-canonical NF-kappaB signal transduction Research
Researchers studying non-canonical NF-kappaB signal transduction-related genes often need to determine whether a candidate gene is causally involved in NIK-dependent p100 processing, p52 generation or downstream transcriptional outputs. EDITGENE provides CRISPR-based cell model services that enable such causal tests in relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for non-canonical NF-kappaB signal transduction research.
Frequently Asked Questions About non-canonical NF-kappaB signal transduction
What is non-canonical NF-kappaB signal transduction?
It is an intracellular signaling cassette defined by GO:0038061 in which NIK-dependent activation of IKKalpha leads to p100 processing and release of active p52 NF-kappaB.
What is the GO ID for non-canonical NF-kappaB signaling?
The GO ID is GO:0038061, with the official name non-canonical NF-kappaB signal transduction.
What genes are involved in non-canonical NF-kappaB signaling?
Core genes include MAP3K14 (NIK), CHUK (IKKalpha), NFKB2 (p100/p52) and RELB, with upstream receptors such as LTBR, CD40, OX40, RANK and TWEAK receptor.
How is the non-canonical NF-kappaB pathway activated?
It is generally activated by ligands of the TNF receptor superfamily, including LTB, CD40, OX40, RANK, TWEAK and BAFF.
What is the difference between canonical and non-canonical NF-kappaB signaling?
The non-canonical pathway depends on NIK and IKKalpha and proceeds through p100 processing to p52, whereas the canonical pathway relies on IKKbeta-mediated IkappaBalpha degradation.
What diseases are linked to non-canonical NF-kappaB signaling?
It is linked to autoimmunity, chronic inflammation and cancer, and is being explored as a therapeutic target.
How do researchers measure non-canonical NF-kappaB activation?
Common readouts include western blotting for p100 and p52, RNA-seq of transcriptional outputs, proteomics and imaging of NF-kappaB nuclear translocation.
Can CRISPR be used to study non-canonical NF-kappaB signaling?
Yes, CRISPR knockout, point-mutation, knock-in and overexpression models are used to test causal roles of pathway components.
What is the role of NIK in non-canonical NF-kappaB signaling?
NIK is the central kinase that initiates the cascade by phosphorylating and activating IKKalpha.
What is p100 processing in non-canonical NF-kappaB signaling?
It is the IKKalpha-dependent cleavage of NF-kappaB2 p100 that releases active p52, the hallmark of this pathway.
Conclusion
GO:0038061, non-canonical NF-kappaB signal transduction, defines a NIK- and IKKalpha-dependent pathway that processes p100 to p52 and controls immune and inflammatory gene programs. Its roles in lymphoid biology, autoimmunity, inflammation and cancer make it a high-value target for mechanistic and therapeutic research. CRISPR-based knockout, point-mutation, knock-in and overexpression models provide the causal tools needed to dissect this pathway in disease-relevant contexts.
References
- 1. Sun SC. 2017. The non-canonical NF-κB pathway in immunity and inflammation.. Nat Rev Immunol 17(9):545-558 PMID: 28580957
- 2. Sun SC. 2011. Non-canonical NF-κB signaling pathway.. Cell Res 21(1):71-85 PMID: 21173796
- 3. Yu H et al.. 2020. Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study.. Signal Transduct Target Ther 5(1):209 PMID: 32958760
- 4. Li D et al.. 2024. IFI35 regulates non-canonical NF-κB signaling to maintain glioblastoma stem cells and recruit tumor-associated macrophages.. Cell Death Differ 31(6):738-752 PMID: 38594444
- 5. Conlon TM et al.. 2020. Inhibition of LTβR signalling activates WNT-induced regeneration in lung.. Nature 588(7836):151-156 PMID: 33149305
- 6. Barbie DA et al.. 2009. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.. Nature 462(7269):108-12 PMID: 19847166
- 7. Chen C et al.. 2026. B cells disrupt tertiary lymphoid structure formation and suppress anti-tumor immunity.. Cancer Cell 44(3):551-566.e17 PMID: 41512868
- 8. Dunphy G et al.. 2018. Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-κB Signaling after Nuclear DNA Damage.. Mol Cell 71(5):745-760.e5 PMID: 30193098
